Professor of Diabetic Medicine
- Diabetes Trials Unit Director
- NIHR Senior Investigator
- Honorary Consultant Physician
The DTU is a fully registered UKCRC Clinical Trials Unit and a founder member of OCDEM. It is one of only a handful of Academic Research Organisations (AROs) worldwide that specialise in performing diabetes-related mega trials. The DTU designs, runs and analyses large-scale Phase III & IV interventional clinical outcome trials nationally and internationally, often in collaboration with other AROs and pharmaceutical companies. Currently the DTU is undertaking 4 large-scale cardiovascular outcome trials in 40 countries, multiple translational trials, holds grants in excess of £60M and has a regional coordinating centre in Beijing, China.
The DTU Translational Trials Group evaluates novel treatments and devices for the therapy of diabetes trials and undertakes research into potential new therapeutic agents in Phase IIa/b trials. The DTU also undertakes major modelling and statistical programmes to utilise fully the data available from its many studies with a particular emphasis on modelling diabetes and cardiovascular disease processes. The DTU Informatics Group designs and maintains the specialist departmental software, the automated data handling facilities and the in-house electronic clinical trials management systems.
Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.
Dennis JM. et al, (2018), Diabetes Care, 41, 705 - 712
Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E. et al, (2018), Diabetes Care, 41, 596 - 603
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Davis TME. et al, (2018), Diabetes Obes Metab
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA. et al, (2018), Lancet Diabetes Endocrinol, 6, 105 - 113
Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.
Holman RR., (2018), Nat Rev Endocrinol, 14, 67 - 68